163 related articles for article (PubMed ID: 3290993)
1. Dopamine receptors in Parkinson's disease.
Hassan MN; Thakar JH
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):173-82. PubMed ID: 3290993
[TBL] [Abstract][Full Text] [Related]
2. L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.
Guttman M; Seeman P
J Neural Transm; 1985; 64(2):93-103. PubMed ID: 2934514
[TBL] [Abstract][Full Text] [Related]
3. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
4. A post-mortem study on striatal dopamine receptors in Parkinson's disease.
Rinne JO; Laihinen A; Lönnberg P; Marjamäki P; Rinne UK
Brain Res; 1991 Aug; 556(1):117-22. PubMed ID: 1834312
[TBL] [Abstract][Full Text] [Related]
5. Central deopaminergic receptor supersensitivity and its relevance to Parkinson's disease.
Pycock CJ; Marsden CD
J Neurol Sci; 1977; 31(1):113-21. PubMed ID: 833607
[TBL] [Abstract][Full Text] [Related]
6. [Dopamine agonists in the therapy of parkinson syndrome].
Kapfhammer HP; Rüther E
Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
[No Abstract] [Full Text] [Related]
7. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.
Leenders KL; Palmer AJ; Quinn N; Clark JC; Firnau G; Garnett ES; Nahmias C; Jones T; Marsden CD
J Neurol Neurosurg Psychiatry; 1986 Aug; 49(8):853-60. PubMed ID: 3091770
[TBL] [Abstract][Full Text] [Related]
8. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease as a model for changes in dopamine receptor dynamics with aging.
Rinne UK
Gerontology; 1982; 28 Suppl 1():35-52. PubMed ID: 7044903
[TBL] [Abstract][Full Text] [Related]
10. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum.
Reches A; Wagner HR; Jackson-Lewis V; Yablonskaya-Alter E; Fahn S
Neurology; 1984 Sep; 34(9):1208-12. PubMed ID: 6540406
[TBL] [Abstract][Full Text] [Related]
11. [Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
Indo T
Rinsho Shinkeigaku; 1984 Oct; 24(10):1008-16. PubMed ID: 6518691
[No Abstract] [Full Text] [Related]
12. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
[TBL] [Abstract][Full Text] [Related]
13. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
Piccini P; Turjanski N; Brooks DJ
J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
[TBL] [Abstract][Full Text] [Related]
14. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.
Muriel MP; Bernard V; Levey AI; Laribi O; Abrous DN; Agid Y; Bloch B; Hirsch EC
Ann Neurol; 1999 Jul; 46(1):103-11. PubMed ID: 10401786
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of striatal dopamine D1 and D2 receptor systems in Parkinson's disease and effects of adrenal medullary transplant.
Joyce JN; Hurtig H
Prog Brain Res; 1990; 82():699-706. PubMed ID: 2290973
[No Abstract] [Full Text] [Related]
16. Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease.
Di Rocco A; Werner P
Ann Neurol; 2000 Jan; 47(1):136-7. PubMed ID: 10632116
[No Abstract] [Full Text] [Related]
17. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.
Rinne UK; Laihinen A; Rinne JO; Någren K; Bergman J; Ruotsalainen U
Mov Disord; 1990; 5(1):55-9. PubMed ID: 2136932
[TBL] [Abstract][Full Text] [Related]
19. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
[TBL] [Abstract][Full Text] [Related]
20. Study on the striatal dopamine availability in Parkinson's disease.
Indo T
Jpn J Med; 1984 Aug; 23(3):228-36. PubMed ID: 6492486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
